Governance
Principles & programme roadmap
How we keep clinical accountability with the pharmaceutical sponsor, and where each workstream actually stands today.
Governance principles
- Sponsor accountability Established Clinical protocol, dose, endpoints, eligibility, safety, and regulatory submissions stay with NWPharmaTech as pharmaceutical sponsor and with investigators, ethics committees and regulators as applicable — not with community polls or token votes.
- Ring-fenced economics Proposed Any programme financing would be limited to expressly granted CHR-P economics. NWPT parent equity is outside this mandate.
- Separation of journeys Working Families and patients are never routed into capital conversations. Investor materials, if offered later, would be private and eligibility-gated.
- Evidence honesty Established Public statements distinguish field context from NWPT-specific evidence. CHR-P risk designation is not a diagnosis of schizophrenia and does not mean transition to psychosis is inevitable.
- No speculative theatre Working This site does not sell tokens, connect wallets, or solicit investment. Financing interfaces remain inactive until legal and operational requirements are met.
- Transparent status Working Unfinished features are labelled “In development.” Illustrative mock data is never presented as live commitments.
Programme roadmap
Status labels below are honest. We do not invent appointments, closing dates, or funding commitments. Approximate figures are planning targets only.
| Horizon | Intent | Lane | Status |
|---|---|---|---|
| Now | Informational site: mission, science context, governance, FAQ | Public | Live / building |
| Near | Version-controlled clinical synopsis; private diligence package for eligible counterparties | Science | In development |
| Near | Private financing materials; IC memo and use-of-proceeds scenarios (labelled illustrative) | Capital / legal | In development |
| Later | Optional permissioned register representation | Capital | Proposed — inactive |
| Later | Larger transition-to-psychosis objectives only if separately powered and financed | Science | Illustrative / later |
| — | Public token sale, DEX liquidity, retail offering, clinical veto by investors, live invest buttons | — | Excluded |
Approximately $10 million is a working fundraising target for planning. It is not committed capital, a validated trial budget, or a priced offer on this website.